NASDAQ$ZVRA
Zevra Therapeutics Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
KemPharm reported Q2 2022 net revenue of $1.3 million and a net loss attributable to common stockholders of $24.0 million, which includes a one-time non-cash expense of $17.7 million related to the acquisition of arimoclomol.
- Acquired substantially all assets and operations of Orphazyme A/S, including arimoclomol, for $12.8 million in cash.
- Resubmission of the arimoclomol NDA for the treatment of NPC is expected as early as Q1 2023.
- Filed IND application for KP1077, an SDX-based product candidate, for the treatment of IH and expects to initiate a Phase 2 trial by the end of 2022.
- Total cash, cash equivalents, and investments were $114.5 million as of June 30, 2022.
Headline financials
Revenue & EPS history
Zevra · Revenue · Quarterly
$1.3M
Forward guidance
KemPharm is well positioned for growth with a strong financial foundation and anticipates numerous milestone opportunities for 2022 and beyond.
Tailwinds
- NDA-stage product with a rapidly advancing clinical-stage pipeline.
- Focus on rare central nervous system, neurodegenerative, and lysosomal storage diseases.
- Commercialization of AZSTARYS by Corium.
- Strong operational and financial foundation.
- Multiple milestone opportunities anticipated for 2022 and beyond.
Headwinds
- Current macroeconomic and global equity market challenges.
- Net loss attributable to common stockholders for Q2 2022 was ($24.0) million.
- Q2 2022 net revenue was $1.3 million, as compared to Q2 2021 net revenue of $12.0 million.
- Expense of $17.7 million during Q2 2022 related to acquired in-process research and development from the arimoclomol asset acquisition during the quarter.
- Research and development expenses were $4.8 million for Q2 2022, as compared to $2.8 million in Q2 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-0.2%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+3.8%
Avg return
30 days after
45%
20 / 44 earnings
Positive
+35.2%
Q2 2015
Best reaction
-19.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.0% | +1.6% | -0.1% | |
| Q4 2025 | +21.3% | +9.4% | +6.5% | |
| Q3 2025 | -9.8% | -6.4% | -13.5% | |
| Q1 2025 | +3.0% | +2.7% | +8.3% | |
| Q4 2024 | -2.1% | -2.1% | +10.5% | |
| Q3 2024 | -3.5% | -3.8% | -5.8% | |
| Q2 2024 | +2.6% | +8.2% | +11.5% | |
| Q1 2024 | -2.7% | -5.5% | -10.1% | |
| Q4 2023 | -13.3% | -13.9% | -23.9% | |
| Q3 2023 | -3.5% | -9.0% | +12.7% | |
| Q2 2023 | +3.8% | -4.2% | -2.7% | |
| Q1 2023 | +3.1% | +27.7% | +37.1% | |
| Q4 2022 | -19.4% | -22.8% | +4.9% | |
| Q3 2022 | -18.3% | -17.6% | -19.7% | |
| Q2 2022 | -5.4% | -14.6% | -4.3% | |
| Q1 2022 | +2.0% | +15.9% | +9.5% | |
| Q4 2021 | -4.7% | -1.3% | -15.3% | |
| Q3 2021 | -0.1% | -2.1% | -9.9% | |
| Q2 2021 | -9.4% | -7.2% | -7.6% | |
| Q1 2021 | +3.4% | +10.8% | +65.9% | |
| Q4 2020 | +19.5% | +14.4% | -8.3% | |
| Q3 2020 | -5.2% | +6.2% | +83.0% | |
| Q2 2020 | +8.7% | +46.8% | +48.9% | |
| Q1 2020 | -13.5% | -21.2% | -27.3% | |
| Q4 2019 | -0.9% | -8.5% | -30.9% | |
| Q3 2019 | +11.3% | -5.5% | -21.6% | |
| Q2 2019 | -15.8% | -18.3% | -25.8% | |
| Q1 2019 | +4.9% | +9.0% | +17.2% | |
| Q4 2018 | -14.6% | -16.2% | -32.4% | |
| Q3 2018 | -1.9% | -6.9% | +8.4% | |
| Q2 2018 | +5.5% | +0.0% | +13.7% | |
| Q1 2018 | +16.8% | +23.8% | +35.6% | |
| Q4 2017 | -9.9% | -13.2% | -29.1% | |
| Q3 2017 | +1.4% | +0.0% | +1.4% | |
| Q2 2017 | +8.5% | -8.5% | +9.3% | |
| Q1 2017 | +0.0% | +3.8% | +2.5% | |
| Q4 2016 | +9.7% | +18.1% | +31.9% | |
| Q3 2016 | +3.8% | +3.8% | -3.8% | |
| Q2 2016 | +0.0% | +7.7% | +22.0% | |
| Q1 2016 | -15.7% | — | — | |
| Q4 2015 | +0.7% | — | — | |
| Q3 2015 | -8.8% | — | — | |
| Q2 2015 | +35.2% | — | — | |
| Q1 2015 | -2.7% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro